Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados

Topics

Temas

Comparison 1 Bicyclol versus benfidate, Outcome 1 Loss of serum HBeAg.
Figuras y tablas -
Analysis 1.1

Comparison 1 Bicyclol versus benfidate, Outcome 1 Loss of serum HBeAg.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Bicyclol versus benfidate, Outcome 2 Seroconversion of HBeAg to HBeAb.
Figuras y tablas -
Analysis 1.2

Comparison 1 Bicyclol versus benfidate, Outcome 2 Seroconversion of HBeAg to HBeAb.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Bicyclol versus benfidate, Outcome 3 Loss of HBV DNA.
Figuras y tablas -
Analysis 1.3

Comparison 1 Bicyclol versus benfidate, Outcome 3 Loss of HBV DNA.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Bicyclol versus benfidate, Outcome 4 Normalisation of ALT and AST.
Figuras y tablas -
Analysis 1.4

Comparison 1 Bicyclol versus benfidate, Outcome 4 Normalisation of ALT and AST.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Bicyclol versus benfidate, Outcome 5 ALT and AST activities.
Figuras y tablas -
Analysis 1.5

Comparison 1 Bicyclol versus benfidate, Outcome 5 ALT and AST activities.

Ir a la figura de la revisiónAbrir en una pestaña nueva
Comparison 1. Bicyclol versus benfidate

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Loss of serum HBeAg Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Totals not selected

1.1 Bicyclol versus bifendate (at the end of treatment)

1

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

1.2 Bicyclol versus bifendate (12 weeks after treatment)

1

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

2 Seroconversion of HBeAg to HBeAb Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Totals not selected

2.1 Bicyclol versus bifendate (at the end of treatment)

1

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

2.2 Bicyclol versus bifendate (12 weeks after treatment)

1

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

3 Loss of HBV DNA Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Totals not selected

3.1 Bicyclol versus benfidate (at the end of scheme)

1

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

3.2 Bicyclol versus benfidate (at week 12 after treatment)

1

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

4 Normalisation of ALT and AST Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Totals not selected

4.1 ALT (at the end of treatment)

1

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

4.2 ALT (12 weeks after treatment)

1

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

4.3 AST (at the end of treatment)

1

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

4.4 AST (12 weeks after treatment)

1

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

5 ALT and AST activities Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

5.1 ALT (at the end of treatment)

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

5.2 ALT (12 weeks after treatment)

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

5.3 AST (at the end of treatment)

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

5.4 AST (12 weeks after treatment)

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]
Figuras y tablas -
Comparison 1. Bicyclol versus benfidate
Ir a la tabla de la revisión